| Id: | acc2317 |
| Group: | 2sens |
| Protein: | SMAD2 |
| Gene Symbol: | SMAD2 |
| Protein Id: | Q15796 |
| Protein Name: | SMAD2_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser467 |
| Site Sequence: | SPSVRCSSMS----------- |
| Disease Category: | Cancer |
| Disease: | Hepatocellular Carcinoma |
| Disease Subtype: | |
| Disease Cellline: | HepG2 |
| Disease Info: | |
| Drug: | NH4Cl |
| Drug Info: | Ammonium chloride (NH4Cl) is an expectorant used to treat respiratory conditions with excessive mucus and a systemic acidifying agent for the treatment of metabolic alkalosis. |
| Effect: | promote |
| Effect Info: | The phosphorylation of SMAD2 can counteract the inhibitory effect of NH4Cl on autophagy. |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 25342595 |
| Sentence Index: | 25342595_6-7 |
| Sentence: | "In order to find out whether NH4Cl may inhibit the autophagy in rapamycin-treated HCC cells through inhibition of SMAD2 signaling, we used transforming growth factor beta1 (TGFbeta1) to induce phosphorylation of SMAD2 in HCC cells. We found that induction of SMAD2 in HCC cells completely abolished the inhibitory effect of NH4Cl on rapamycin-induced autophagy in HCC cells, suggesting that NH4Cl inhibits autophagy of HCC cells through inhibiting SMAD2 signaling." |
Sequence & Structure:
MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| SMAD2-Ser118 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -1.1 | ||||
| HGSC | |||||
| ccRCC | 0.246 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.854 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SMAD2-Thr172 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.002 |
| COAD | -0.816 |
| HGSC | 1.954 |
| ccRCC | -0.467 |
| GBM | |
| HNSC | -0.115 |
| LUAD | -0.6 |
| LUSC | 0.334 |
| non_ccRCC | -1.011 |
| PDAC | -0.765 |
| UCEC | 1.485 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 467 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 ; 35022323 |
| S | 467 | U | Marfan syndrome | Phosphorylation | 15731757 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
